{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:19:27Z","timestamp":1788347967482,"version":"build-2803163510"},"reference-count":61,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Sci.","Medical Sciences"],"abstract":"<jats:p>Prostate cancer is the most commonly diagnosed non-cutaneous malignancy among men in the United States and remains a leading cause of cancer-related mortality. Its marked biological, molecular, and histopathological heterogeneity creates a central diagnostic challenge: identifying clinically significant disease while limiting unnecessary biopsy and overdiagnosis of tumors unlikely to affect survival or quality of life. Although prostate-specific antigen (PSA) remains the foundation of early detection, its limited cancer specificity has driven the development of increasingly risk-adapted diagnostic pathways. Contemporary evaluation integrates clinical risk assessment and PSA-derived measures with selectively used blood- and urine-based biomarkers, multiparametric magnetic resonance imaging (mpMRI), image-guided biopsy, histopathological classification, genomic risk assessment, and molecular imaging. Biomarkers such as the Prostate Health Index, 4Kscore, IsoPSA, MiCheck, SelectMDx, and ExoDx may refine biopsy decisions in appropriately selected patients but should be interpreted according to the clinical setting, decision threshold, and surrounding diagnostic pathway. Prostate MRI and PI-RADS-based assessment have become central to pre-biopsy evaluation, while MRI-targeted biopsy improves detection of Grade Group \u2265 2 disease. Increasing use of the transperineal biopsy route offers comparable cancer detection with a lower infectious risk. Following diagnosis, Grade Group, adverse histological features, clinical risk models, and selected tissue-based genomic classifiers provide complementary prognostic information. PSMA PET\/CT has further improved staging of selected patients with higher-risk disease and localization of biochemical recurrence. Precision diagnostics must also account for disease phenotypes that may not be adequately represented by conventional PSA- and imaging-based pathways, including intraductal carcinoma, cribriform architecture, ductal adenocarcinoma, and neuroendocrine prostate cancer. Emerging approaches, including artificial intelligence-assisted MRI interpretation, digital pathology, high-frequency micro-ultrasound, liquid biopsy, alternative molecular radiotracers, and multi-omic integration, show increasing potential but remain at different stages of validation and clinical adoption. This review critically examines contemporary prostate cancer diagnostics within United States clinical practice, distinguishing established guideline-supported approaches from selectively used adjuncts and emerging technologies. Particular emphasis is placed on diagnostic performance in context, clinical utility, external validation, healthcare equity, regulatory considerations, and the need to demonstrate that increasing diagnostic complexity translates into meaningful improvements in patient care.<\/jats:p>","DOI":"10.3390\/medsci14050541","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:57:23Z","timestamp":1788346643000},"page":"541","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision Diagnostics in Prostate Cancer: Integrating Biomarkers, Imaging, Genomics, and Artificial Intelligence in Contemporary United States Practice"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9537-2274","authenticated-orcid":false,"given":"Moustafa","family":"Kardjadj","sequence":"first","affiliation":[{"name":"dicentra, Toronto, ON M4W 3E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"ref_1","unstructured":"American Cancer Society (2026). Key Statistics for Prostate Cancer, American Cancer Society."},{"key":"ref_2","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","unstructured":"Cancer Genome Atlas Research Network (2015). The molecular taxonomy of primary prostate cancer. Cell, 163, 1011\u20131025."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Hugosson","year":"2014","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"US Preventive Services Task Force (2018). Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA, 319, 1901\u20131913.","DOI":"10.1001\/jama.2018.3710"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JU.0000000000003491","article-title":"Early detection of prostate cancer: AUA\/SUO Guideline Part I: Prostate cancer screening","volume":"210","author":"Wei","year":"2023","journal-title":"J. Urol."},{"key":"ref_7","unstructured":"National Comprehensive Cancer Network (2026, June 01). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. Version 1, Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?id=1459."},{"key":"ref_8","unstructured":"European Association of Urology (2026). EAU Guidelines on Prostate Cancer, EAU Guidelines Office."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/JU.0000000000003492","article-title":"Early detection of prostate cancer: AUA\/SUO Guideline Part II: Considerations for a prostate biopsy","volume":"210","author":"Wei","year":"2023","journal-title":"J. Urol."},{"key":"ref_10","first-page":"26","article-title":"Updates of prostate cancer from the 2022 World Health Organization classification of the urinary and male genital tumors","volume":"3","author":"Guo","year":"2023","journal-title":"J. Clin. Transl. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.urolonc.2024.01.037","article-title":"Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management","volume":"42","author":"Shi","year":"2024","journal-title":"Urol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/pros.24664","article-title":"Diagnosis and management of neuroendocrine prostate cancer","volume":"84","author":"Chan","year":"2024","journal-title":"Prostate"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of ^18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: Results from the CONDOR phase III, multicenter study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1470-2045(24)00220-1","article-title":"Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): An international, paired, non-inferiority, confirmatory study","volume":"25","author":"Saha","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2025.3579","article-title":"Microultrasonography-guided vs. MRI-guided biopsy for prostate cancer diagnosis: The OPTIMUM randomized clinical trial","volume":"333","author":"Kinnaird","year":"2025","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/his.70046","article-title":"The Genitourinary Pathology Society and International Society of Urological Pathology Joint Expert Consultation recommendations on intraductal carcinoma of the prostate","volume":"88","author":"Shah","year":"2026","journal-title":"Histopathology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/PAS.0000000000001728","article-title":"ISUP consensus definition of cribriform pattern prostate cancer","volume":"45","author":"Berney","year":"2021","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e222246","DOI":"10.1001\/jamanetworkopen.2022.2246","article-title":"Trends in incidence of metastatic prostate cancer in the US","volume":"5","author":"Desai","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2022.03.007","article-title":"Deconstructing, addressing, and eliminating racial and ethnic inequities in prostate cancer care","volume":"82","author":"Nyame","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s42003-021-02140-y","article-title":"Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences","volume":"4","author":"Rayford","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/jama.279.19.1542","article-title":"Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial","volume":"279","author":"Catalona","year":"1998","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.juro.2014.10.121","article-title":"The Prostate Health Index selectively identifies clinically significant prostate cancer","volume":"193","author":"Loeb","year":"2015","journal-title":"J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2014.10.021","article-title":"A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer","volume":"68","author":"Parekh","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"408.e9","DOI":"10.1016\/j.urolonc.2022.06.002","article-title":"Clinical validation of IsoPSA, a single parameter, structure-focused assay for improved detection of prostate cancer: A prospective, multicenter study","volume":"40","author":"Klein","year":"2022","journal-title":"Urol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"454.e9","DOI":"10.1016\/j.urolonc.2023.08.005","article-title":"Development and evaluation of the MiCheck\u00ae Prostate test for clinically significant prostate cancer","volume":"41","author":"Shore","year":"2023","journal-title":"Urol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s41391-021-00367-8","article-title":"Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: A prospective, multicenter study in biopsy-na\u00efve men","volume":"24","author":"Hendriks","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41391-021-00456-8","article-title":"Predicting high-grade prostate cancer at initial biopsy: Clinical performance of the ExoDx (EPI) Prostate IntelliScore test in three independent prospective studies","volume":"25","author":"Margolis","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.juro.2012.08.219","article-title":"Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: Results of the MATLOC study","volume":"189","author":"Stewart","year":"2013","journal-title":"J. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate Imaging Reporting and Data System version 2.1: 2019 update of Prostate Imaging Reporting and Data System version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2023.12.015","article-title":"Transperineal versus transrectal magnetic resonance imaging-targeted and systematic prostate biopsy to prevent infectious complications: The PREVENT randomized trial","volume":"86","author":"Hu","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A contemporary prostate cancer grading system: A validated alternative to the Gleason score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/01.ju.0000158155.33890.e7","article-title":"The University of California, San Francisco Cancer of the Prostate Risk Assessment score: A straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy","volume":"173","author":"Cooperberg","year":"2005","journal-title":"J. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.urology.2016.01.012","article-title":"Decipher genomic classifier measured on prostate biopsy predicts metastasis risk","volume":"90","author":"Klein","year":"2016","journal-title":"Urology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.eururo.2014.05.004","article-title":"A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling","volume":"66","author":"Klein","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/bjc.2015.223","article-title":"Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort","volume":"113","author":"Cuzick","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1001\/jama.2024.6695","article-title":"Long-term outcomes in patients using protocol-directed active surveillance for prostate cancer","volume":"331","author":"Newcomb","year":"2024","journal-title":"JAMA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/JU.0000000000003892","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO Guideline Part I: Introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1200\/JCO-24-02608","article-title":"Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline","volume":"43","author":"Yu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: The PROPHECY study","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_47","unstructured":"U.S. Food and Drug Administration (2025). 510(k) Premarket Notification K252608: AI-Rad Companion Prostate MR."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1002\/jmri.29660","article-title":"Assessing the performance of artificial intelligence assistance for prostate MRI: A two-center study involving radiologists with different experience levels","volume":"61","author":"Sun","year":"2025","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41698-023-00424-6","article-title":"An international multi-institutional validation study of the algorithm for prostate cancer detection and Gleason grading","volume":"7","author":"Tolkach","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41379-022-01077-9","article-title":"Artificial intelligence system shows performance at the level of uropathologists for the detection and grading of prostate cancer in core needle biopsy: An independent external validation study","volume":"35","author":"Jung","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Kopytov, S.A., Sagitova, G.R., Guschin, D.Y., Egorova, V.S., Zvyagin, A.V., and Rzhevskiy, A.S. (2025). Circulating tumor DNA in prostate cancer: A dual perspective on early detection and advanced disease management. Cancers, 17.","DOI":"10.3390\/cancers17152589"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.juro.2015.12.093","article-title":"Assessing cancer risk on novel 29 MHz micro-ultrasound images of the prostate: Creation of the Micro-Ultrasound Protocol for Prostate Risk Identification","volume":"196","author":"Ghai","year":"2016","journal-title":"J. Urol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/JU.0000000000005082","article-title":"External validation of the PRI-MUS scoring system: A secondary analysis of the OPTIMUM randomized controlled trial","volume":"216","author":"Lazarovich","year":"2026","journal-title":"J. Urol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2967\/jnumed.123.267260","article-title":"EAU Section of Urological Imaging. A systematic review on the diagnostic value of fibroblast activation protein inhibitor PET\/CT in genitourinary cancers","volume":"65","author":"Hagens","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6502","DOI":"10.1007\/s00330-023-09619-8","article-title":"PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies","volume":"33","author":"Cohen","year":"2023","journal-title":"Eur. Radiol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Hachem, S., Yehya, A., El Masri, J., Mavingire, N., Johnson, J.R., Dwead, A.M., Kattour, N., Bouchi, Y., Kobeissy, F., and Rais-Bahrami, S. (2024). Contemporary update on clinical and experimental prostate cancer biomarkers: A multi-omics-focused approach to detection and risk stratification. Biology, 13.","DOI":"10.3390\/biology13100762"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"h5527","DOI":"10.1136\/bmj.h5527","article-title":"STARD 2015: An updated list of essential items for reporting diagnostic accuracy studies","volume":"351","author":"Bossuyt","year":"2015","journal-title":"BMJ"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e070904","DOI":"10.1136\/bmj-2022-070904","article-title":"DECIDE-AI Expert Group. Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI","volume":"377","author":"Vasey","year":"2022","journal-title":"BMJ"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e078378","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: Updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"ref_60","unstructured":"International Medical Device Regulators Forum (IMDRF), and Artificial Intelligence\/Machine Learning-enabled Working Group (2026, June 01). Good Machine Learning Practice for Medical Device Development: Guiding Principles; IMDRF\/AIML WG\/N88 FINAL; IMDRF. Available online: https:\/\/www.imdrf.org\/documents\/good-machine-learning-practice-medical-device-development-guiding-principles."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/5\/541\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:09:24Z","timestamp":1788347364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/5\/541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["medsci14050541"],"URL":"https:\/\/doi.org\/10.3390\/medsci14050541","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}